Please login to the form below

Not currently logged in
Email:
Password:

MISSION appoints Paul Wallace as chief business officer

Joins from Medivir where he was executive VP and head of business development

edit-Mission-Paul_WallaceCancer biotech MISSION Therapeutics has named Paul Wallace as chief business officer.

Wallace has worked in business development roles within drug discovery companies for almost 20 years, most recently at Medivir where he was executive VP and head of business development as well as member of the executive management team responsible for strategic and operational leadership, R&D portfolio management and investment planning.

Commenting on his appointment, Wallace said: “I am delighted to be joining the MISSION team at a time when the commercialisation of certain assets is an increasingly promising prospect.

“The diversity of assets created is testimony to the rigour of MISSION's screening platform in this critically important, but hitherto difficult, area of drug discovery.”

During his time at Medivir, he played a key role in the execution of over 25 partnership deals, eight products were taken into clinical development and two drugs were launched.

In his new role, Wallace will construct future business strategy, including the potential of development partnerships.

Anker Lundemose, MISSION CEO, added: “Paul's extensive business development experience will be invaluable in helping us find the right strategic partnerships to fully realise the potential of these assets.

“Our core focus is cancer, but our platform discovery approach has yielded highly promising molecules for other indications, such as Parkinson's disease. We see partnering as an attractive option for taking these non-core projects forward.”

17th March 2015

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

Here at Cuttsy+Cuttsy, we believe in making the world a better place by bringing trusted, accessible information to all and...

Latest intelligence

Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...
Jonathan Cooke
The fight against antimicrobial resistance
By Jonathan Cooke...